Individualized immunotherapy for immune reconstitution-associated cortical encephalitis in an HIV-positive cryptococcal meningitis patient: a case report

Read full text Summarise with VIRAT
Authors: Wen Wang, Shi Tang, Jun Yang, YH Wen
Cited by: 0
References: 13

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Neurological immune reconstitution inflammatory syndrome (IRIS) in HIV can present variably. We report a case of steroid-dependent, recurrent cortical encephalitis with a distinctive migratory Magnetic Resonance Imaging (MRI) pattern following cryptococcal meningitis. Case presentation: A 38-year-old male with advanced HIV (CD4 11/μL) developed cryptococcal meningitis. After antifungal induction and switching to effective antiretroviral therapy (bictegravir/emtricitabine/tenofovir alafenamide), he suffered recurrent neurological episodes. Serial brain MRIs showed sequentially appearing and resolving T2/Fluid-Attenuated Inversion Recovery (FLAIR) hyperintensities in the bilateral frontal lobes, left cingulate gyrus, and left occipital cortex, despite negative infectious and autoimmune workup. Symptoms were steroid-responsive but relapsed upon tapering. Lasting remission was achieved only after adding mycophenolate mofetil (MMF), allowing corticosteroid withdrawal. Conclusions: This case describes a "migratory cortical encephalitis" phenotype of Central Nervous System (CNS)-IRIS. It highlights that cortical grey matter can be the primary target in severe IRIS and illustrates the utility of steroid-sparing agents like MMF for managing refractory, steroid-dependent neuroinflammation in this context.

Fields of Study & Subjects

Infectious Diseases and Tuberculosis Fungal Infections and Studies HIV Research and Treatment

Publication details

Journal / source
Frontiers in Immunology
Volume
17
Pages
1805701–1805701
Publication date
30 March 2026
Language
EN